Menu Search
Equities

Wellbeing Digital Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SQ2:STU

Wellbeing Digital Sciences Inc

Actions
  • Price (EUR)0.0045
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 16 2023.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company. The Company is focused on the development and implementation of clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. It operates through three segments: Wellbeing & IRP; KGK Science and Mindscape. It operates medical clinics across North America to help its patients access plant-based medicines, psychedelics, and other forms of mental health care, all of which have the potential to heal them of their physical and/or emotional pain. Its subsidiaries include Mindscape Ketamine & Infusions Therapy LLC, KGK Science Inc. and Integrated Rehab and Performance Ltd. It is supported by a network of North American clinics that provide therapies and other types of treatment to patients, as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.

  • Revenue in USD (TTM)4.73m
  • Net income in USD-18.51m
  • Incorporated2017
  • Employees--
  • Location
    Wellbeing Digital Sciences Inc275 Dundas Street,, Unit A1605LONDON N6B 3L1CanadaCAN
  • Phone+1 (604) 687-2038
  • Fax+1 (604) 351-6647
  • Websitehttps://www.wellbeingdigital.co/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.